David Oliver Francis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Oliver Francis has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Natalia Arroyo
University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison
6 shared publicationsSara Fernandes-Taylor
Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison
5 shared publications- Andrew Jay Bowen
MetroHealth Medical Center Cleveland Ohio USA
4 shared publications Peter Nordby
Wisconsin Surgical Outcomes Research Program, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison
4 shared publications- Sydney Ring
Department of Otorhinolaryngology‐Head and Neck Surgery Mayo Clinic Rochester Minnesota USA
4 shared publications - Alexander Gelbard
Vanderbilt University Medical Center, Nashville
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 February 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (2) , e2559852
Overdiagnosis of Papillary Thyroid Cancer
Importance: The magnitude of thyroid cancer overdiagnosis in the US, accounting for the true increase in underlying disease, has not been quantified. The implications of reducing thyroid ultrasonography use for these rates has not been calculated. Objective: To estimate US population-level rates of papillary thyroid cancer (PTC) overdiagnosis, and to identify the implications of reducing thyroid ultrasonography use for thyroid cancer incidence and overall mortality. Design, Setting, and Participants: This study used a validated simulation model (Papillary Thyroid Carcinoma Microsimulation Model) of contemporary PTC incidence in the adult US population between 1991 and 2019. Data analysis was conducted from June 2024 to August 2025. Exposures: Thyroid cancer incidence and referrals for ultrasonography of nonpalpable thyroid nodules. Main Outcomes and Measures: Model-estimated relative and absolute rates of PTC overdiagnosis, stratified by sex. The model estimated changes in the rates of thyroid cancer incidence and overall mortality if ultrasonography rates were reduced. Results: The simulation included all adults, aged 18 years or older, in the US. Between 1991 and 2019, the model estimated that 72% to 94% of PTC cases were overdiagnosed. While the proportion of overdiagnosis was slightly higher for women compared with men (75%-95% vs 63%-90%), the absolute rate of overdiagnosis was higher among women compared with men (13-17 per 100 000 individuals vs 3-5 per 100 000 individuals). This rate translated into 443 212 to 573 705 women and 107 804 to 154 504 men who were overdiagnosed with PTC over 28 years. Reducing use of thyroid ultrasonography for nonpalpable nodules by 33% and 67% would have decreased PTC incidence by 17% (18 to 15 per 100 000 individuals) and 41% (18 to 11 per 100 000 individuals) in 2019, respectively, a less than 0.1% change in overall mortality. Conclusions and Relevance: This study found that thyroid cancer overdiagnosis in the US remains substantial, even after accounting for possible increases in true incidence. This finding suggests an opportunity to reduce unnecessary thyroid ultrasonography referrals, particularly for nonpalpable nodules, and to reduce unnecessary diagnoses and treatment-related harms without increasing mortality.
- 2 February 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (2) , e2559852
Top Cited PapersOpen AccessOverdiagnosis of Papillary Thyroid Cancer
Importance: The magnitude of thyroid cancer overdiagnosis in the US, accounting for the true increase in underlying disease, has not been quantified. The implications of reducing thyroid ultrasonography use for these rates has not been calculated. Objective: To estimate US population-level rates of papillary thyroid cancer (PTC) overdiagnosis, and to identify the implications of reducing thyroid ultrasonography use for thyroid cancer incidence and overall mortality. Design, Setting, and Participants: This study used a validated simulation model (Papillary Thyroid Carcinoma Microsimulation Model) of contemporary PTC incidence in the adult US population between 1991 and 2019. Data analysis was conducted from June 2024 to August 2025. Exposures: Thyroid cancer incidence and referrals for ultrasonography of nonpalpable thyroid nodules. Main Outcomes and Measures: Model-estimated relative and absolute rates of PTC overdiagnosis, stratified by sex. The model estimated changes in the rates of thyroid cancer incidence and overall mortality if ultrasonography rates were reduced. Results: The simulation included all adults, aged 18 years or older, in the US. Between 1991 and 2019, the model estimated that 72% to 94% of PTC cases were overdiagnosed. While the proportion of overdiagnosis was slightly higher for women compared with men (75%-95% vs 63%-90%), the absolute rate of overdiagnosis was higher among women compared with men (13-17 per 100 000 individuals vs 3-5 per 100 000 individuals). This rate translated into 443 212 to 573 705 women and 107 804 to 154 504 men who were overdiagnosed with PTC over 28 years. Reducing use of thyroid ultrasonography for nonpalpable nodules by 33% and 67% would have decreased PTC incidence by 17% (18 to 15 per 100 000 individuals) and 41% (18 to 11 per 100 000 individuals) in 2019, respectively, a less than 0.1% change in overall mortality. Conclusions and Relevance: This study found that thyroid cancer overdiagnosis in the US remains substantial, even after accounting for possible increases in true incidence. This finding suggests an opportunity to reduce unnecessary thyroid ultrasonography referrals, particularly for nonpalpable nodules, and to reduce unnecessary diagnoses and treatment-related harms without increasing mortality.
- Open Access
- 15 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340347
Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017–2023)
Introduction: The Coronavirus 2019 (COVID-19) pandemic disrupted healthcare delivery across the United States, leading to a sharp decline in outpatient visits. Given that thyroid nodule evaluation and diagnosis typically occur in outpatient settings, we hypothesized that these disruptions would reduce thyroid cancer incidence. This study evaluates trends in thyroid cancer diagnosis, treatment, and outcomes at a U.S. comprehensive cancer center from 2017 to 2023. Methods: We included adults with pathologically confirmed thyroid cancer diagnosis between January 1, 2017, and December 31, 2023. Primary analyses assessed (1) annual percent change (APC) in thyroid cancer incidence from 2017–2023 and (2) incidence trends across three periods: pre-pandemic (Jan 2017–Mar 2020), pandemic (Apr 2020–Mar 2021), and COVID-years (Apr 2021–Dec 2023). Annual incidence rates were calculated using the total number of individuals cared for within our health system each year as the denominator. Secondary outcomes included tumor size, extent and timing of surgery, and 1-year all-cause mortality across time periods. Results: Among 1,031 patients (68% women, 92% White, mean age 52 ± 15.5), age- and sex-adjusted thyroid cancer incidence declined from 34 to 15.6 per 100,000 persons between 2017 and 2022, with an average APC of –14.4%. Diagnoses rose slightly in 2023 (21 per 100,000) compared to 2022 but remained 38% below 2017 levels. No significant differences were observed in tumor size, surgical treatment, gender ratio, or 1-year all-cause mortality across timeframes. Conclusion: Age- and sex-adjusted annual incidence of thyroid cancer declined steadily from 2017 to 2022. The annual decrease in thyroid cancer continued through the pandemic years. Tumor size and mortality remained stable across all years evaluated. The increase in diagnoses noted in 2023 may be a correction due to missed cases during the years of the pandemic or could represent a new steady state incidence after years of decline.
- 15 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340347
Open AccessImpact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017–2023)
Introduction: The Coronavirus 2019 (COVID-19) pandemic disrupted healthcare delivery across the United States, leading to a sharp decline in outpatient visits. Given that thyroid nodule evaluation and diagnosis typically occur in outpatient settings, we hypothesized that these disruptions would reduce thyroid cancer incidence. This study evaluates trends in thyroid cancer diagnosis, treatment, and outcomes at a U.S. comprehensive cancer center from 2017 to 2023. Methods: We included adults with pathologically confirmed thyroid cancer diagnosis between January 1, 2017, and December 31, 2023. Primary analyses assessed (1) annual percent change (APC) in thyroid cancer incidence from 2017–2023 and (2) incidence trends across three periods: pre-pandemic (Jan 2017–Mar 2020), pandemic (Apr 2020–Mar 2021), and COVID-years (Apr 2021–Dec 2023). Annual incidence rates were calculated using the total number of individuals cared for within our health system each year as the denominator. Secondary outcomes included tumor size, extent and timing of surgery, and 1-year all-cause mortality across time periods. Results: Among 1,031 patients (68% women, 92% White, mean age 52 ± 15.5), age- and sex-adjusted thyroid cancer incidence declined from 34 to 15.6 per 100,000 persons between 2017 and 2022, with an average APC of –14.4%. Diagnoses rose slightly in 2023 (21 per 100,000) compared to 2022 but remained 38% below 2017 levels. No significant differences were observed in tumor size, surgical treatment, gender ratio, or 1-year all-cause mortality across timeframes. Conclusion: Age- and sex-adjusted annual incidence of thyroid cancer declined steadily from 2017 to 2022. The annual decrease in thyroid cancer continued through the pandemic years. Tumor size and mortality remained stable across all years evaluated. The increase in diagnoses noted in 2023 may be a correction due to missed cases during the years of the pandemic or could represent a new steady state incidence after years of decline.
- Open Access
- 13 September 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 14-17
Medical Therapy Algorithm With Telehealth Reduces Procedures and Transfers for Peritonsillar Abscess
- 13 September 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 14-17
Open AccessMedical Therapy Algorithm With Telehealth Reduces Procedures and Transfers for Peritonsillar Abscess
- 29 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4767-4773
Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Background: Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods: We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results: Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions: Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence: 4.
- 29 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4767-4773
Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Background: Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods: We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results: Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions: Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence: 4.
- Open Access
- 8 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4793-4799
Es‐ CoPE : Translation and Validation of the Vocal Cord Paralysis Experience Questionnaire for Spanish Speakers
Objectives: Dysphonia, dysphagia, and dyspnea are frequent symptoms of unilateral vocal fold paralysis (UVFP). The CoPE patient‐reported outcome measure (PROM) evaluates the disability associated with UVFP but has only been validated in English. This study aims to translate, cross‐culturally adapt, and validate the Spanish version of CoPE (Es‐CoPE). Methods: This prospective, single‐center study included 50 Spanish‐speaking UVFP patients and 50 controls at a tertiary care voice clinic. CoPE was adapted through forward and reverse translation using rigorous methodology. Es‐CoPE was evaluated for test–retest reliability, internal consistency, criterion validity (score comparison to gold standard VHI‐10 and EAT‐10), and construct validity through factor analysis. Results: UVFP and control groups had similar demographics (24 female/26 male cases vs. 22 female/28 male controls). Test–retest reliability was confirmed with a Pearson correlation of 0.87 (95% CI 0.81–0.91) and for its subscales (voice: r = 0.784 [95% CI 0.69–0.85], swallowing: r = 0.789 [95% CI 0.70–0.85], psychosocial: r = 0.704 [95% CI 0.58–0.79]). Es‐CoPE showed construct validity as scores were significantly higher in UVFP patients than in controls (mean 34.68 [28.53–40.82 ± 21.63] vs. 4.94 [2.37–7.51 ± 9.04]). Factor analysis showed most items had strong factor loadings (> 0.8). Cronbach's alpha coefficient was 0.96, indicating strong internal consistency. The Es‐CoPE voice subscale correlated with VHI‐10 ( r = 0.79 cases, r = 0.52 controls), and the swallowing subscale correlated with EAT‐10 ( r = 0.81 cases, r = 0.57 controls), demonstrating criterion validity. Conclusion: The Spanish version of the CoPE is as reliable and valid as the English version, which fills the gap in the ability to assess the patient‐reported disability associated with UVFP in patients in the Spanish‐speaking population. Level of evidence: 2
- 8 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (12) , 4793-4799
Open AccessEs‐ CoPE : Translation and Validation of the Vocal Cord Paralysis Experience Questionnaire for Spanish Speakers
Objectives: Dysphonia, dysphagia, and dyspnea are frequent symptoms of unilateral vocal fold paralysis (UVFP). The CoPE patient‐reported outcome measure (PROM) evaluates the disability associated with UVFP but has only been validated in English. This study aims to translate, cross‐culturally adapt, and validate the Spanish version of CoPE (Es‐CoPE). Methods: This prospective, single‐center study included 50 Spanish‐speaking UVFP patients and 50 controls at a tertiary care voice clinic. CoPE was adapted through forward and reverse translation using rigorous methodology. Es‐CoPE was evaluated for test–retest reliability, internal consistency, criterion validity (score comparison to gold standard VHI‐10 and EAT‐10), and construct validity through factor analysis. Results: UVFP and control groups had similar demographics (24 female/26 male cases vs. 22 female/28 male controls). Test–retest reliability was confirmed with a Pearson correlation of 0.87 (95% CI 0.81–0.91) and for its subscales (voice: r = 0.784 [95% CI 0.69–0.85], swallowing: r = 0.789 [95% CI 0.70–0.85], psychosocial: r = 0.704 [95% CI 0.58–0.79]). Es‐CoPE showed construct validity as scores were significantly higher in UVFP patients than in controls (mean 34.68 [28.53–40.82 ± 21.63] vs. 4.94 [2.37–7.51 ± 9.04]). Factor analysis showed most items had strong factor loadings (> 0.8). Cronbach's alpha coefficient was 0.96, indicating strong internal consistency. The Es‐CoPE voice subscale correlated with VHI‐10 ( r = 0.79 cases, r = 0.52 controls), and the swallowing subscale correlated with EAT‐10 ( r = 0.81 cases, r = 0.57 controls), demonstrating criterion validity. Conclusion: The Spanish version of the CoPE is as reliable and valid as the English version, which fills the gap in the ability to assess the patient‐reported disability associated with UVFP in patients in the Spanish‐speaking population. Level of evidence: 2
- Open Access
- 12 June 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (4) , 938-946
Job Accommodations and Job Loss From Unilateral Vocal Fold Paralysis
Objective: Unilateral vocal fold paralysis (UVFP) is a debilitating injury that affects a person's ability to communicate and swallow. Although clinical aspects are understood, how UVFP affects a person's employment and job security is poorly characterized. This study aims to elucidate how frequently patients request job accommodations or experience job loss related to UVFP.Study Design: Cross‐sectional survey.Setting: Thirty‐four US tertiary care voice centers.Methods: We analyzed data from a prospective cohort of patients with UVFP recruited from 34 vocal Cord Paralysis Experience (CoPE) collaborative voice centers. Sociodemographic information, clinical and treatment history, and patient‐reported outcome measures were collected. Patients also provided employment information, whether they requested job accommodations, and if they experienced job loss due to UVFP.Results: In all, 613 participants (mean age 58 years, 65% women, 84% Caucasian) enrolled in CoPE. In total, 64 (10%) had requested job accommodations, and 46 (7.5%) reported job loss due to UVFP. Women (odds ratio [OR] 2.6, 95% CI: 1.4‐5.0, P = .004) and participants with higher levels of education were more likely to request work accommodations (OR 4.5, 95% CI: 1.4‐14.7, P = .01).Conclusion: UVFP has major impacts on employment with 1 in 10 patients requesting job accommodations and 1 in 13 experiencing job loss. Our results raise awareness of the importance of timely, effective treatment for UVFP and should alert treating clinicians to provide support to patients who may require job accommodations.
- 12 June 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (4) , 938-946
Open AccessJob Accommodations and Job Loss From Unilateral Vocal Fold Paralysis
Objective: Unilateral vocal fold paralysis (UVFP) is a debilitating injury that affects a person's ability to communicate and swallow. Although clinical aspects are understood, how UVFP affects a person's employment and job security is poorly characterized. This study aims to elucidate how frequently patients request job accommodations or experience job loss related to UVFP.Study Design: Cross‐sectional survey.Setting: Thirty‐four US tertiary care voice centers.Methods: We analyzed data from a prospective cohort of patients with UVFP recruited from 34 vocal Cord Paralysis Experience (CoPE) collaborative voice centers. Sociodemographic information, clinical and treatment history, and patient‐reported outcome measures were collected. Patients also provided employment information, whether they requested job accommodations, and if they experienced job loss due to UVFP.Results: In all, 613 participants (mean age 58 years, 65% women, 84% Caucasian) enrolled in CoPE. In total, 64 (10%) had requested job accommodations, and 46 (7.5%) reported job loss due to UVFP. Women (odds ratio [OR] 2.6, 95% CI: 1.4‐5.0, P = .004) and participants with higher levels of education were more likely to request work accommodations (OR 4.5, 95% CI: 1.4‐14.7, P = .01).Conclusion: UVFP has major impacts on employment with 1 in 10 patients requesting job accommodations and 1 in 13 experiencing job loss. Our results raise awareness of the importance of timely, effective treatment for UVFP and should alert treating clinicians to provide support to patients who may require job accommodations.
- Open Access
- 5 June 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (11) , 4312-4316
Endoscopic Management of a Hypopharyngeal‐Subglottic Fistula: Case Series and Literature Review
A rare complication of prolonged intubation or laryngeal radiation is destruction of the posterior cricoid cartilage with resultant hypopharyngeal-subglottic fistula leading to aspiration and inability to consume a regular diet. We describe a step-by-step endoscopic approach to the closure of a hypopharyngeal-subglottic fistula. This technique successfully closed the fistula in two patients and allowed the safe resumption of an oral diet.
- 5 June 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (11) , 4312-4316
Open AccessEndoscopic Management of a Hypopharyngeal‐Subglottic Fistula: Case Series and Literature Review
A rare complication of prolonged intubation or laryngeal radiation is destruction of the posterior cricoid cartilage with resultant hypopharyngeal-subglottic fistula leading to aspiration and inability to consume a regular diet. We describe a step-by-step endoscopic approach to the closure of a hypopharyngeal-subglottic fistula. This technique successfully closed the fistula in two patients and allowed the safe resumption of an oral diet.
- Open Access
- 21 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3766-3773
Characterizing Disease Severity Through Surgical Recurrence Rates in Idiopathic Subglottic Stenosis
Objective: There is currently not a marker of disease severity in idiopathic subglottic stenosis (iSGS). Our objective was to characterize iSGS patients' disease severity using endoscopic surgery rates.Methods: This was a two‐center retrospective analysis of iSGS patients with a minimum of 4 years of follow up following an initial endoscopic procedure (laser wedge excision (LWE) or endoscopic dilation (ED)). Disease severity was classified into Groups A–C, based on whether patients had fewer (Group A), the same number (Group B), or more surgeries (Group C) in years 3–5 compared to years 1 and 2. Disease severity proportions were compared across institutions using chi‐square analysis. Nonparametric testing compared clinical characteristics such as age, BMI, and GERD across severity groups.Results: There were 104 patients from institution 1 and 53 patients from institution 2 that were all female and predominantly Caucasian. Both institutions had clinically and statistically similar proportions of patients in Group A (64% vs. 62%), Group B (20% vs. 19%), and Group C (16% vs. 19%) disease (p > 0.05). No clinical characteristic (e.g., age, sex, race, BMI, GERD) was associated with disease severity.Conclusion: Across tertiary care institutions there is a consistent proportion of iSGS patients who either demonstrate nonrecurrent/decelerating (Group A), stable but persistent (Group B), or rapidly recurring disease (Group C). Two‐year surgery rates appear to be an important timepoint for providing expectations to patients on the likelihood of possessing severe disease.Level of Evidence: 4
- 21 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3766-3773
Open AccessCharacterizing Disease Severity Through Surgical Recurrence Rates in Idiopathic Subglottic Stenosis
Objective: There is currently not a marker of disease severity in idiopathic subglottic stenosis (iSGS). Our objective was to characterize iSGS patients' disease severity using endoscopic surgery rates.Methods: This was a two‐center retrospective analysis of iSGS patients with a minimum of 4 years of follow up following an initial endoscopic procedure (laser wedge excision (LWE) or endoscopic dilation (ED)). Disease severity was classified into Groups A–C, based on whether patients had fewer (Group A), the same number (Group B), or more surgeries (Group C) in years 3–5 compared to years 1 and 2. Disease severity proportions were compared across institutions using chi‐square analysis. Nonparametric testing compared clinical characteristics such as age, BMI, and GERD across severity groups.Results: There were 104 patients from institution 1 and 53 patients from institution 2 that were all female and predominantly Caucasian. Both institutions had clinically and statistically similar proportions of patients in Group A (64% vs. 62%), Group B (20% vs. 19%), and Group C (16% vs. 19%) disease (p > 0.05). No clinical characteristic (e.g., age, sex, race, BMI, GERD) was associated with disease severity.Conclusion: Across tertiary care institutions there is a consistent proportion of iSGS patients who either demonstrate nonrecurrent/decelerating (Group A), stable but persistent (Group B), or rapidly recurring disease (Group C). Two‐year surgery rates appear to be an important timepoint for providing expectations to patients on the likelihood of possessing severe disease.Level of Evidence: 4
- 15 April 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (9) , 3280-3286
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Objective: While endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.Methods: This was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.Results: A total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).Conclusion: LWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.
- 15 April 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (9) , 3280-3286
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Objective: While endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.Methods: This was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.Results: A total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).Conclusion: LWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.
- Top Cited Papers
- 8 April 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 322-336
The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease
INTRODUCTION: The term laryngopharyngeal reflux (LPR) is frequently applied to aerodigestive symptoms despite lack of objective reflux evidence. The aim of this initiative was to develop a modern care paradigm for LPR supported by otolaryngology and gastroenterology disciplines. METHODS: A 28-member international interdisciplinary working group developed practical statements within the following domains: definition/terminology, initial diagnostic evaluation, reflux monitoring, therapeutic trials, behavioral factors and therapy, and risk stratification. Literature reviews guided statement development and were presented at virtual/in-person meetings. Each statement underwent 2 or more rounds of voting per the RAND Appropriateness Method; statements reaching appropriateness with ≥80% agreement are included as recommendations. RESULTS: The term laryngopharyngeal symptoms (LPS) applies to aerodigestive symptoms with potential to be induced by reflux and include cough, voice change, throat clearing, excess throat phlegm, and throat pain. Laryngopharyngeal reflux disease (LPRD) refers to patients with LPS and objective evidence of reflux. Importantly, the presence of LPS does not equate to LPRD. Laryngoscopy has value in assessing for nonreflux laryngopharyngeal processes, but laryngoscopic findings alone cannot diagnose LPRD. LPS patients should be categorized as with or without concurrent esophageal reflux symptoms. While lifestyle modification and empiric trials of acid suppression ± alginates are appropriate when esophageal reflux symptoms coexist, upper endoscopy and ambulatory reflux monitoring are required for LPRD diagnosis when symptoms persist, when LPS is isolated, or when management needs to be escalated to include invasive antireflux management. The two recommended ambulatory reflux monitoring modalities, 24-hour pH-impedance and 96-hour wireless pH monitoring, are not mutually exclusive with distinct roles for the evaluation of LPS. Laryngeal hyperresponsiveness and hypervigilance commonly contribute to both LPS and LPRD presentations and are responsive to laryngeal recalibration therapy and neuromodulators. DISCUSSION: The San Diego Consensus represents the formal modern-day interdisciplinary care paradigm to evaluate and manage LPS and LPRD.
- 8 April 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 322-336
Top Cited PapersThe San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease
INTRODUCTION: The term laryngopharyngeal reflux (LPR) is frequently applied to aerodigestive symptoms despite lack of objective reflux evidence. The aim of this initiative was to develop a modern care paradigm for LPR supported by otolaryngology and gastroenterology disciplines. METHODS: A 28-member international interdisciplinary working group developed practical statements within the following domains: definition/terminology, initial diagnostic evaluation, reflux monitoring, therapeutic trials, behavioral factors and therapy, and risk stratification. Literature reviews guided statement development and were presented at virtual/in-person meetings. Each statement underwent 2 or more rounds of voting per the RAND Appropriateness Method; statements reaching appropriateness with ≥80% agreement are included as recommendations. RESULTS: The term laryngopharyngeal symptoms (LPS) applies to aerodigestive symptoms with potential to be induced by reflux and include cough, voice change, throat clearing, excess throat phlegm, and throat pain. Laryngopharyngeal reflux disease (LPRD) refers to patients with LPS and objective evidence of reflux. Importantly, the presence of LPS does not equate to LPRD. Laryngoscopy has value in assessing for nonreflux laryngopharyngeal processes, but laryngoscopic findings alone cannot diagnose LPRD. LPS patients should be categorized as with or without concurrent esophageal reflux symptoms. While lifestyle modification and empiric trials of acid suppression ± alginates are appropriate when esophageal reflux symptoms coexist, upper endoscopy and ambulatory reflux monitoring are required for LPRD diagnosis when symptoms persist, when LPS is isolated, or when management needs to be escalated to include invasive antireflux management. The two recommended ambulatory reflux monitoring modalities, 24-hour pH-impedance and 96-hour wireless pH monitoring, are not mutually exclusive with distinct roles for the evaluation of LPS. Laryngeal hyperresponsiveness and hypervigilance commonly contribute to both LPS and LPRD presentations and are responsive to laryngeal recalibration therapy and neuromodulators. DISCUSSION: The San Diego Consensus represents the formal modern-day interdisciplinary care paradigm to evaluate and manage LPS and LPRD.